Last reviewed · How we verify

Difluprednate Ophthalmic

Thomas M. Lietman · FDA-approved active Small molecule

Difluprednate Ophthalmic is a Corticosteroid Small molecule drug developed by Thomas M. Lietman. It is currently FDA-approved for Post-operative inflammation following ocular surgery, Anterior uveitis, Inflammatory conditions of the anterior segment of the eye.

Difluprednate is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.

Difluprednate is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Post-operative inflammation following ocular surgery, Anterior uveitis, Inflammatory conditions of the anterior segment of the eye.

At a glance

Generic nameDifluprednate Ophthalmic
SponsorThomas M. Lietman
Drug classCorticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Difluprednate is a fluorinated prednisolone derivative designed for ophthalmic use with enhanced corneal penetration. It inhibits inflammatory mediators, reduces leukocyte infiltration, and suppresses immune cell activation in ocular tissues. The drug is particularly effective for post-operative inflammation and anterior uveitis due to its superior bioavailability in the anterior segment of the eye.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Difluprednate Ophthalmic

What is Difluprednate Ophthalmic?

Difluprednate Ophthalmic is a Corticosteroid drug developed by Thomas M. Lietman, indicated for Post-operative inflammation following ocular surgery, Anterior uveitis, Inflammatory conditions of the anterior segment of the eye.

How does Difluprednate Ophthalmic work?

Difluprednate is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.

What is Difluprednate Ophthalmic used for?

Difluprednate Ophthalmic is indicated for Post-operative inflammation following ocular surgery, Anterior uveitis, Inflammatory conditions of the anterior segment of the eye.

Who makes Difluprednate Ophthalmic?

Difluprednate Ophthalmic is developed and marketed by Thomas M. Lietman (see full Thomas M. Lietman pipeline at /company/thomas-m-lietman).

What drug class is Difluprednate Ophthalmic in?

Difluprednate Ophthalmic belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is Difluprednate Ophthalmic in?

Difluprednate Ophthalmic is FDA-approved (marketed).

What are the side effects of Difluprednate Ophthalmic?

Common side effects of Difluprednate Ophthalmic include Elevated intraocular pressure, Posterior subcapsular cataract, Ocular irritation or discomfort, Secondary ocular infection.

What does Difluprednate Ophthalmic target?

Difluprednate Ophthalmic targets Glucocorticoid receptor and is a Corticosteroid.

Related